196 related articles for article (PubMed ID: 35300208)
1. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Huang J; Guo Y; Huang W; Hong X; Quan Y; Lin L; Zhou J; Liang L; Zhang Y; Zhou J; Cai M; Zhu K
J Hepatocell Carcinoma; 2022; 9():157-170. PubMed ID: 35300208
[TBL] [Abstract][Full Text] [Related]
2. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.
Li J; Jia Y; Shao C; Li Y; Song J
Ther Clin Risk Manag; 2023; 19():329-339. PubMed ID: 37041973
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Yang X; Deng H; Sun Y; Zhang Y; Lu Y; Xu G; Huang X
J Hepatocell Carcinoma; 2023; 10():303-313. PubMed ID: 36874252
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
Front Oncol; 2022; 12():917353. PubMed ID: 36226061
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.
Liu K; Wu J; Xu Y; Li D; Huang S; Mao Y
Onco Targets Ther; 2022; 15():1079-1094. PubMed ID: 36212725
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.
Huang N; Zhao C; Hu X; Zhang C; Xiong F; Huang W; Da L; Shen Y; Wu H
Transl Cancer Res; 2022 Jan; 11(1):252-261. PubMed ID: 35261901
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
12. Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
Falette-Puisieux M; Nault JC; Bouattour M; Lequoy M; Amaddeo G; Decaens T; Di Fiore F; Manfredi S; Merle P; Baron A; Locher C; Pellat A; Coriat R
Ther Adv Med Oncol; 2023; 15():17588359231189425. PubMed ID: 37547443
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study.
Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY
Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036
[TBL] [Abstract][Full Text] [Related]
14. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.
Xu Y; Fu S; Liu K; Mao Y; Wu J
Ther Clin Risk Manag; 2023; 19():853-863. PubMed ID: 37899984
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
Ren SH; Cui ZL; Lang MR; Li Q; Zhang W; Fang F; Wu Q; Cui YL; Li HK; Chen P; Zhang Y; Song T
J Gastrointest Oncol; 2022 Jun; 13(3):1266-1277. PubMed ID: 35837206
[TBL] [Abstract][Full Text] [Related]
17. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.
Adhoute X; De Matharel M; Mineur L; Pénaranda G; Ouizeman D; Toullec C; Tran A; Castellani P; Rollet A; Oules V; Perrier H; Si Ahmed SN; Bourliere M; Anty R
World J Gastrointest Oncol; 2022 Aug; 14(8):1510-1527. PubMed ID: 36160737
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study.
Tu X; Yang J; Zheng Y; Liang C; Tao Q; Tang X; Liu Z; Jiang L; He Z; Xie F; Zheng Y
Int Immunopharmacol; 2022 Dec; 113(Pt B):109401. PubMed ID: 36395672
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.
Yang W; Li T; Bai Y; Long Y; Gao M; Wang T; Jing F; Zhang F; Tao H; Ma J; Wang L; Hu Y
Front Oncol; 2023; 13():1147903. PubMed ID: 37124534
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
